HIV/AIDS schistosomiasis
Conditions
Interventions
Praziquantel
Efavirena
Ritonavir
Sponsors
AiBST
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Male Black Zimbabwean Age between 18 and 40 years BMI between 18 and 30 HIV, Hepatitis B and C negative Able to give consent Non-smoking Lab screening and ECG within the limits stipulated in the protocol Healthy as determined by medical examination
Exclusion criteria
Exclusion criteria: HIV positive any current or past history of psychiatric disorder subjects receiving any prescription or over the counter product use of any recreational drug subjects who have eaten grapefruit or drunk grapefruit juice during the last 15 days before administration of study drug subjects who had xanthine containing beverages (coffee, tea, chocolates, etc) 48 hours prior to study drug administration history of hepatic, renal, GI, heart, lung, neurological, endocrine, chronic infections or disease subjects suffering from any acute disease at screening or check in Alanine S. Transaminase (AST)/ Alanine L. Transaminase (ALT) >3 times upper limit of normal (ULN) Bilirubin >2.5 times ILN Amylase > 2 times ULN Absolute Neutrophil Count 50 000 cells/mm3 serum creatinine >2.5 mg/dl
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC, Cmax | — |
Secondary
| Measure | Time frame |
|---|---|
| Tmax, half life and elimination rate constant | — |
Countries
Zimbabwe
Contacts
Public ContactGeorginah Nyabadza
Clinical Trial Manager
Outcome results
None listed